<span item_type="fundamental" item_id="832e5010ad7d4249812f2083a66dd4f6" counter_id="ST/US/SABSW" env="prod"></span><span item_type="announcement" item_id="514178937370380161" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.56.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Grant Revenue</strong>: No revenue recognized for the three months ended March 31, 2025, compared to $944,575 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: Net loss of $5,196,773 for the three months ended March 31, 2025, compared to $5,025,745 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li><li><strong>Research and Development Expenses</strong>: $7,657,321 for the three months ended March 31, 2025, a decrease from $8,146,070 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li><li><strong>General and Administrative Expenses</strong>: $3,114,781 for the three months ended March 31, 2025, a decrease from $4,189,121 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $7,797,217 for the three months ended March 31, 2025, compared to - $10,750,009 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li><li><strong>Net Cash Provided by (Used in) Investing Activities</strong>: $4,671,103 for the three months ended March 31, 2025, compared to - $31,359,207 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: - $173,985 for the three months ended March 31, 2025, compared to - $394,418 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Changes in Fair Value of Warrant Liabilities</strong>: $5,035,769 for the three months ended March 31, 2025, compared to $5,468,219 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: SAB Biotherapeutics plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate the therapeutic candidate in adult and pediatric patients with new-onset type 1 diabetes.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li><li><strong>Non-Core Business</strong>: The company does not expect to generate revenues during the development phase of its primary pipeline development target of Type 1 diabetes, which remains independently financed as it explores potential partnerships, co-development opportunities, and licensing arrangements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1833214/000095017025067554/sabs-20250331.htm"></span></li></ul>

SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.56